A clinical stage cardiovascular company is gearing up for market. They need an all-encompassing team to support their venture.

A breath of fresh air.

InCarda Therapeutics

InCarda Therapeutics, a biopharmaceutical company out of Palo Alto, CA, discovered a faster and more-effective way to treat cardiovascular disease: via the inhalation route. This novel approach brings a huge advantage – it offers a lower dose, with more control, ensuring the effects are extremely targeted and patients are not over-exposed to the drug.

Founded
2009

Partner Since
2013

Industry
Life Sciences

Location
Bay Area, CA

Communicating care.

When we met, InCarda was riding strong momentum from a Series A round. They were embarking on human trials and needed a communications strategy to reach prospective subjects who were in need of a better solution.

In conjunction, planning was underway for a Series B to engage a wider audience of investors, Key Opinion Leaders (KOLs) and early adopters.

Together we set out on key initiatives…

Key Initiatives Included:

Developed authentic brand and value proposition to attract investors.

1/5

Key Initiatives Included:

Partner with commercial & regulatory team on product packaging branding.

2/5

Key Initiatives Included:

Direct engagement with executive team for culture-building activities for recruitment and retention.

3/5

Key Initiatives Included:

Enhance digital footprint for US and OUS market engagement.

4/5

Key Initiatives Included:

Align with regulatory team in developing patient and physician facing Instructions for Use.

5/5

“I cannot say enough good things about the experience working with Howbridge. The value of our partnership goes well beyond tactical elements.

I liked the way they became a strategic partner for InCarda – as a startup, we needed a more integrated, comprehensive approach. I’ve already recommended Howbridge to several people, and the team is currently working with many of my parent companies.”

– Grace E. Colón, Ph.D., Board Member & Former Chief Executive Officer, InCarda Therapeutics

Impact:
A brand built for international growth.

Through our strategic insight, InCarda achieved key milestones, including:

Seed to Series D completion.

Attracted new top-level VC firm investment.

Oversubscribed Series B.

First Patients enrolled in Phase 2 Clinical Trial.

Attracted top BOD and SAB expansion with top VC advisors.